Literature DB >> 8600070

Ovarian mucinous tumors of low malignant potential: a clinicopathologic study of 54 tumors of intestinal and müllerian type.

S Siriaunkgul1, K M Robbins, L McGowan, S G Silverberg.   

Abstract

We have reviewed 44 mucinous intestinal (MI) and 10 mucinous mullerian (MM) tumors of low malignant potential (LMP) seen at The George Washington University Medical Center. As previously reported by Rutgers and Scully, MMLMP tumors occurred in younger women, were generally smaller and more frequently bilateral, had a papillary rather than multicystic appearance, and lacked goblet cells. All patients with MMLMP tumors were recurrence-free at last follow-up, including three whose tumors were microinvasive. Patients with MILMP tumors also all did well regardless of tumor grade, with the exception of a single patient with bilateral grade 1 ovarian tumors, an appendiceal villous adenoma, and pseudomyxoma peritonei. Microinvasion was also seen in four of these tumors, none of which recurred. Review of the literature suggests that MILMP tumors without stromal invasion but with either prominent cell stratification or marked nuclear atypia may have a worse prognosis than those lacking these features, but probably largely because of a correlation with higher stage disease. We believe that tumors of this sort should not be diagnosed as "noninvasive carcinomas," but should be sectioned more extensively for evidence of stromal invasion and subjected to careful staging. If the tumor is still noninvasive and in stage I after these procedures, the likelihood of treatment failure appears to be in the range of 1-3%.

Entities:  

Mesh:

Year:  1995        PMID: 8600070     DOI: 10.1097/00004347-199507000-00002

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  6 in total

1.  HER2-positive mucinous adenocarcinomas of the ovary have an expansile invasive pattern associated with a favorable prognosis.

Authors:  Sang Kyum Kim; Nam Hoon Cho
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

2.  CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours.

Authors:  Filippo Fraggetta; Giuseppe Pelosi; Alessia Cafici; Paolo Scollo; Paolo Nuciforo; Giuseppe Viale
Journal:  Virchows Arch       Date:  2003-10-24       Impact factor: 4.064

3.  Association of pancreatic adenocarcinoma up-regulated factor expression in ovarian mucinous adenocarcinoma with poor prognosis.

Authors:  Sang Kyum Kim; Si Young Song; Sunghoon Kim; Nam Hoon Cho; Ga Won Yim; Sang Wun Kim; Young Tae Kim; Eun Ji Nam
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

Review 4.  Ovarian Seromucinous Tumors: Pathogenesis, Morphologic Spectrum, and Clinical Issues.

Authors:  Michiko Nagamine; Yoshiki Mikami
Journal:  Diagnostics (Basel)       Date:  2020-01-31

5.  Role of Retinoblastoma Protein Family (Rb/p105 and Rb2/p130) Expression in the Histopathological Classification of Borderline Ovarian Tumors.

Authors:  Valeria Masciullo; Paola Valdivieso; Giulia Amadio; Angela Santoro; Giuseppe Angelico; Alessandro Sgambato; Silvia Boffo; Antonio Giordano; Giovanni Scambia; Gian Franco Zannoni
Journal:  Front Med (Lausanne)       Date:  2020-11-11

6.  Allelic loss at 19q12 and Xq11-12 predict an adverse clinical outcome in patients with mucinous ovarian tumours of low malignant potential.

Authors:  K Nakayama; Y Takebayashi; K Hata; R Fujiwaki; K Iida; M Fukumoto; K Miyazaki
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.